SHORT REPORT



Bone marrow infiltration pattern in patients with intravascular large B-cell lymphoma diagnosed by random skin biopsy

¹ Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan

² Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research. Tokyo, Japan

Correspondence

Kosei Matsue, MD, PhD, Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa-shi, Chiba 296-8602, Japan.

Email: koseimatsue@gmail.com

Kosei Matsue¹ 💿 🕴 Yoshiaki Abe¹ 💿 👘 Kentaro Narita¹ 👘 Hiroki Kobayashi¹ Akihiro Kitadate¹ Daisuke Miura¹ Masami Takeuchi¹ Kengo Takeuchi²

Abstract

We retrospectively analyzed bone marrow (BM) infiltration pattern in consecutive 30 intravascular large B-cell lymphoma (IVLBCL) patients diagnosed by random skin biopsy (RSB). BM infiltration of lymphoma was observed in 18 patients (60.0%), including five patients with the intrasinusoidal pattern with minimal extravasation, eight patients with the mixed of intrasinusoidal and scattered/interstitial or nodular infiltration, and five patients with the nodular/diffuse pattern. Twelve patients were negative for lymphoma infiltration. BM histology of patients with IVLBCL were diverse and frequently discordant with those of other site of IVLBCL lesions. BM biopsy had a poorer diagnostic performance for detecting intravascular features.

KEYWORDS

bone marrow biopsy, incisional random skin biopsy, intravascular large B-cell lymphoma

1 INTRODUCTION

Intravascular large B-cell lymphoma (IVLBCL), an extremely rare form of extranodal large B-cell lymphoma, is characterized by selective proliferation of lymphoma cells within the lumina of small blood vessels [1]. IVLBCL diagnosis remains challenging because it usually lacks approachable nodal or tumorous lesions and targeted organ biopsies are often impracticable. Bone marrow biopsy (BMB) has been widely used as a less-invasive diagnostic method for patients suspected IVL-BCL in many Western and Asian countries [2]; however, its diagnostic sensitivity for IVLBCL remains unclear. Our recent study indicates that the incisional random skin biopsy (RSB) has an excellent sensitivity for IVLBCL [3]. However, we noted that some patients diagnosed as IVL-BCL using RSB showed a different pathognomonic lymphoma infiltration patterns on BM histology [4]. This prompted us to reconsider the diagnostic value of BMB in patients suspected of IVLBCL. The objectives of this study were to investigate the correlations between the histopathology of BMB and incisional RSB as well as to determine the diagnostic value of BMB for IVLBCL.

2 | MATERIALS AND METHODS

2.1 | Study design and patients

We retrospectively analyzed 30 consecutive patients diagnosed as IVL-BCL using incisional RSB at Kameda Medical Center, Japan between June 2006 and December 2019. Patients diagnosed as IVLBCL other than skin or bone marrow and were excluded from the study. Incisional RSB were performed before initiating any form of therapy who were suspicious of IVLBCL [3]. Bone marrow specimens were obtained from the iliac crest as a part of initial screening for extend of disease. RSB were obtained from three separate, fat-containing areas as previously described [3-5]. Two patients were diagnosed as having IVLBCL by

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

^{© 2020} The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

MATSUE ET AL.



lung and adrenal biopsy, respectively and these two patients were not received RSB. Histopathological findings were interpreted by an expert hematopathologist (K.T.). Written informed consent was obtained from all participating patients or their families. The study was conducted according to the Declaration of Helsinki and was approved by the review board of Kameda Medical Center.

2.2 | Identification and categorization of marrow involvement in patients with IVLBCL

The presence of lymphoma was identified based on immunohistochemistry using an antibody specific for CD20 or CD79a. The anti-CD31 antibody was used to demonstrate the endothelial cells for confirming the localization of lymphoma cells within the capillary lumina. The marrow infiltration pattern of IVLBCL was categorized as a negative pattern, intrasinusoidal pattern with or without minimal extravasation [6] (Figure 1A), intrasinusoidal pattern with substantial scattered/interstitial extravasation (Figure 1B), or nodular/diffuse pattern (Figure 1C) according to our recent report [4]. Patients who had an intrasinusoidal pattern with substantial scattered/interstitial extravasation or nodular/diffuse pattern alone without definite intravascular lesions in tissues other than bone marrow were not considered as IVLBCL.

2.3 | Statistical analysis

Relationships between baseline characteristics and marrow infiltration patterns were assessed using one-way analysis of variance, the Kruskal-Wallis test, or chi-squared tests as appropriate. The probabilities of overall survival (OS) were estimated using the Kaplan-Meier method and compared using the log-rank test. A two-tailed *P*-value of <.05 was considered statistically significant. Statistical analysis was performed using the R software, version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria).

3 | RESULTS

3.1 Demographic and baseline patient characteristics of patients

Baseline characteristics of all the IVLBCL patients are shown in Table 1. All 30 patients showed typical features of IVLBCL on incisional RSB histology. The median patient age was 72 years and 16 patients (57.1%) were male. The median observation period was 21.5 months. Twenty-five patients (89.3%) presented with cytopenia (neutrophils < 1.5×10^9 /L, hemoglobin < 10.0 g/dL, or platelets < 100×10^9 /L) and 13 (46.4%) had hemophagocytic

282

		Bone marrow infiltration p	attern			
			Intrasinusoidal with minimal	Intrasinusoidal with Scattered/interstitial		
	All patients	Negative (%)	extravasation (%)	(%)	Nodular/diffuse (%)	
Clinical factors	n = 30	n = 12 (40)	n = 5 (16.7)	n = 8 (26.7)	n = 5 (16.7)	P-value
Age, years [median (range)]	71 (54, 87)	72 (60, 83)	81 (63, 87)	69 (57, 74)	76 (54, 83)	.16
Sex, Male (%)	18 (60.0)	5 (41.7)	3 (60.0)	6 (20.0)	4 (40.0)	.26
WBC, $\times 10^{9}$ /L [median (IQR)]	5500 (3500, 8200)	8200 (5525, 8425)	3500 (3000, 4500	5200 (3450, 6200)	5700 (5500, 6000)	.339
Hemoglobin, g/dL [median (IQR)]	8.9 (8.0, 12.0)	9.3 (8.0, 11.3)	7.6 (7.0, 9.0)	11.0 (10.0, 12.0)	10.0 (9.0, 12.0)	.125
Platelet, $\times 10^{9}$ /L [median (IQR)]	7.4 (5.0, 15.0)	8.3 (7.0, 14.0)	6.5 (6.0, 19.0)	5.9 (3.9, 12.3)	4.0 (3.0, 6.0)	.251
Hemophagocytic syndrome (%)	12 (40.0)	6 (50.0)	1 (20.0)	4 (50.0)	1 (20.0)	.055
Splenomegaly (%)	23 (82.1)	11 (91.7)	2 (40.0)	7 (87.5)	3 (60.0)	.71
LDH, U/L [median (IQR)]	896 (589, 1285)	773 (582, 1172)	427 (416, 1120)	1248 (987, 1329)	847 (713,1112)	.489
sIL-2R, U/mL [median (IQR)]	6780 (4695, 10296)	6347 (4119, 9287)	9593 (2679, 10060)	6985 (4743, 11717)	7120 (6780, 19558)	.583
Treatment (%)						
Rituximab plus CHOP	25 (89.3)	12 (92.3)	4 (80.0)	5 (80.0)	5 (100)	NA
Rituximab plus EPOCH	3 (10.0)	1 (7.7)	1 (20.0)	1 (20.0)	0 (0.0)	
Other	2 (6.7)	0 (0.0)	0 (0.0)	1	0 (0.0)	NA
Outcome (%)						
Alive	16 (53.3)	6 (50.0)	3 (60.0)	5 (62.5)	2 (40.0)	NA
Dead	14 (47.7)	6 (50.0)	2 (40.0)	3 (37.5)	3 (60.0)	
Abbreviations: CHOP, cyclophosphamide, ac genase; sIL-2R, soluble interleukin-2 receptc	driamycin, vincristine, and pred or; IQR, inter quarter range; N,	Inisone; EPOCH, etoposide, pre A, not assessed.	ednisolone, vincristine, cyclop	hosphamide, and adriamycin; I	QR, interquartile range; LDH,	actate dehydro-

 TABLE 1
 Baseline clinical characteristics of patients

MATSUE ET AL.

WILEY 283

syndrome. All but two patients underwent immunochemotherapy with rituximab plus CHOP (cyclophosphamide, adriamycin, vincristine, and prednisolone) (n = 25) or CHOP-like (n = 3) regimens. Two patients did not received chemotherapy because of refusal and died before diagnosis.

3.2 Diagnostic performance of BMB in IVLBCL patients initially diagnosed using RSB

Marrow involvement of large B-cell lymphoma was detected in 18 patients (60.0%) but not in the remaining 12 (40%) patients. Accordingly, the positivity of BMB for large B-cell lymphoma diagnosis, not IVLBCL, was 53.6%. An intrasinusoidal marrow infiltration pattern with or without minimal extravasation that was diagnostic for IVLBCL was observed only in five patients. Therefore, the sensitivity of BMB for IVLBCL diagnosis was only 16.7% (95% confidence interval, 5.6-34.7%).

3.3 | Prevalence and clinical relevance of each marrow histology pattern

The intrasinusoidal pattern with or without minimal extravasation, the intrasinusoidal pattern with substantial scattered/interstitial infiltration, and the nodular/diffuse patterns were observed in five, eight, and five patients among 18 patients with positive BMB, respectively. We found four patients had mixed marrow patterns in a single marrow specimen: one patient with the intrasinusoidal and scattered interstitial patterns and three with the scattered interstitial and nodular/diffuse patterns. Clinical characteristics of patients according the marrow pattern are summarized in Table 1. Patients with a nodular/diffuse pattern had appeared to have higher lactate dehydrogenase (LDH) levels. No inter-group differences in other clinical factors, including treatment approaches, were detected. In addition, no survival difference was observed between the patients with or without bone marrow infiltration (median, not reached vs 27.7 months; Figure S1).

4 | DISCUSSION

In the present study, we found considerable discordance between BMB- and RSB-based histological findings in IVLBCL patients. To the best of our knowledge, no other study has compared the diagnostic performances and histological findings between BMB and RSB in IVL-BCL patients using a sizeable cohort.

BMB is widely accepted as a screening test for IVLBCL, especially in patients without apparent skin lesions [2]. However, in our study, BMB exhibited approximately 60% sensitivity for detecting lymphoma involvement and only 16.7% specificity for identifying the IVLBCL lesions, respectively. The low sensitivity of BMB for IVLBCL diagnosis is of particular importance because this disease has several clinical and prognostic peculiarities (eg, neural or pulmonary involvement) that distinguish it from other large B-cell lymphomas [7-12]. Our findings suggest that a significant proportion of IVLBCL patients might have been missed and/or diagnosed with diffuse large B-cell lymphoma (DLBCL) of the bone marrow if they were not evaluated using incisional RSB [13].

In this study, we assessed marrow histology in patients diagnosed with IVLBCL using the IVLBCL lesions other than bone marrow. The high incidence of negative marrow infiltration (13/28, 46.4%) in RSB positive IVLBCL patients may support the notion that RSB may detect IVLBCL at an early disease stage. Indeed, patients with scattered/interstitial or nodular/diffuse marrow patterns tended to have higher LDH levels than those without such patterns; furthermore, patients with negative marrow infiltration experienced relatively longer OS rates despite undergoing similar treatments, although this difference was likely not statistically significant probably because of the small sample size.

Intriguingly, the BM histological findings in IVLBCL patients were highly heterogeneous. Approximately 20% of the patients showed unequivocal nodular/diffuse infiltration that are incongruous with both skin histology and the expected disease-related features [2]. The findings appear to be consistent with those in several previous studies, in which patients with rare IVLBCLs presented with concomitant bulky cardiac DLBCL masses, [14] nodal DLBCL lesions at relapse, [15] or extensive extravascular proliferation and tumour growth [16]. It is possible that IVLBCL may merely be an angiotrophic manifestation of a certain type of DLBCL, and may change its histological features according to the involved sites and microenvironments. These phenomena might also be associated with the loss of adhesion molecules in IVLBCL [17]. Alternatively, IVLBCL could be included in the recent proposed category of distinct subtype of "bone marrow-liver-spleen" (BLS) type DLBCL that is characterized by bone marrow involvement of large Bcell lymphoma with or without liver and/or spleen, but no lymph node or other extranodal sites, and is often associated with fever, anemia, and hemophagocytosis [18].

This study has several limitations, including its retrospective nature and single-institution design. Bone marrow histology was usually performed unilateral iliac crest, while RSB was performed from three different sites of the body. However, this study included the largest number of IVLBCL patients investigated to date, and they were thoroughly evaluated using both pretreatment BMB and incisional RSB.

In conclusion, this study demonstrated the heterogeneity of marrow histology and the low incidence of pathognomonic, intra-sinusoidal marrow infiltration patterns in newly diagnosed IVLBCL patients diagnosed by RSB. BMB was found to have a low sensitivity for detecting intravascular features. These findings may provide new insights into IVLBCL biology and shed light on the development of useful diagnostic strategies for IVLBCL.

ACKNOWLEDGMENTS

The authors would like to thank the staff of the Department of Dermatology, Kameda Medical Center, Kameda, Japan, for their assistance in making this study possible. The authors also thank Kaori Kumada (Department of Clinical Pathology, Kameda Medical Center, Chiba, Japan) for collecting pathology specimens and outstanding technical assistance. Lastly, the authors thank Editage (www.editage.jp) for English language editing.

AUTHOR CONTRIBUTIONS

K.M. and Y.A. planned and designed the study, collected data, wrote the manuscript, and provided patient care. K.N., H.K., A.K., D.M., and M.T. provided patient care. K.T. interpreted all histology findings. All authors reviewed and approved the manuscript.

CONFLICT OF INTEREST

K.M. received honoraria from Celgene Corporation, Janssen Japan, and Takeda pharmaceutical company. For the remaining authors, no conflict of interest was declared.

ORCID

Kosei Matsue D https://orcid.org/0000-0002-8669-9865 Yoshiaki Abe D https://orcid.org/0000-0002-1021-7911 Akihiro Kitadate D https://orcid.org/0000-0003-3218-2446

REFERENCES

- 1. Nakamura S, Ponzoni M, Campo E. Intravascular large B-cell lymphoma. In: Swerdlow S, Campo E, Harris N, et al. WHO Classification of Tumours of Haematopoietic & Lymphoid Tissues, 4th ed. Lyon, France: International Agency for Research on Cancer; 2017; 317-318.
- Ponzoni M, Campo E, Nakamura S. Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks. Blood 2018;132:1561-1567. PMID:30111607
- Matsue K, Abe Y, Kitadate A, Miura D, Narita K, Kobayashi H, et al. Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Blood 2019;133 (11):1257-1259. PMID:30647028
- Matsue K, Abe Y, Narita K, Kobayashi H, Kitadate A, Takeuchi M, et al. Diagnosis of intravascular large B cell lymphoma: novel insight into clinicopathological features from 42 patients at a single institution over 20 years. Br J Haematol. 2019;187(3):328-336. PMID:31267524
- Enzan N, Kitadate A, Tanaka A, Matsue K. Incisional random skin biopsy, not punch biopsy, is an appropriate method for diagnosis of intravascular large B-cell lymphoma: A clinicopathological study of 25 patients. Br J Dermatol. 2019, 181, 200-201.
- Ponzoni M, Ferreri AJ, Campo E, Facchetti F, Mazzucchelli L, Yoshino T, et al. Definition, diagnosis, and management of intravascular large Bcell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol. 2007; 25: 3168–3173.
- Ferreri AJ, Campo E, Seymour JF, Willemze R, llariucci F, Ambrosetti A, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol. 2004;127:173-183.

- Murase T, Yamaguchi M, Suzuki R, Okamoto M, Sato Y, Tamaru J, et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 2007;109:478-485.
- Martusewicz-Boros M, Wiatr E, Radzikowska E, Roszkowski-Sliz K, Langfort R, Pulmonary intravascular large B-cell lymphoma as a cause of severe hypoxemia. J Clin Oncol. 2007;25:2137-2139.
- Shimada K, Murase T, Matsue K, Okamoto M, Ichikawa N, Tsukamoto N, et al. Central nervous system involvement in intravascular large Bcell lymphoma: a retrospective analysis of 109 patients. Cancer Sci. 2010;101:1480-1486.
- Matsue K, Hayama BY, Iwama K, Koyama T, Fujiwara H, Yamakura M, et al. High frequency of neurolymphomatosis as a relapse disease of intravascular large B-cell lymphoma. Cancer 2011;117:4512-4521.
- Abe Y, Narita K, Kobayashi H, Takeuchi M, Kikuchi Y, Ouchi T, et al. Clinical value of abnormal findings on brain magnetic resonance imaging in patients with intravascular large B-cell lymphoma. Ann Hematol. 2018;97:2345-2352.
- Martinez A, Ponzoni M, Agostinelli C, Hebeda KM, Matutes E, Peccatori J, et al. Primary bone marrow lymphoma: an uncommon extranodal presentation of aggressive non-hodgkin lymphomas. Am J Surg Pathol. 2012;36:296-304.
- Abe Y, Usui Y, Narita K, Takeuchi M, Matsue K. Concomitant subcutaneous intravascular lymphoma lesions in a patient with cardiac diffuse large B-cell lymphoma: is intravascular lymphoma a distinct clinical entity? Int J Hematol. 2018;108:637-639.
- Zhao XF, Sands AM, Ostrow PT, Halbiger R, Conway JT, Bagg A. Recurrence of nodal diffuse large B-cell lymphoma as intravascular large B-cell lymphoma: is an intravascular component at initial diagnosis predictive? Arch Pathol Lab Med. 2005;129:391-394.
- Thomas CA, Guileyardo JM, Krause JR. An intravascular lymphoma with extravascular tendencies. Bayl Univ Med Cent Proc. 2014;27:341-343.
- Ponzoni M, Arrigoni G, Gould VE, Del Curto B, Maggioni M, Scapinello A, et al. Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Hum Pathol. 2000;31:220-226.
- lioka F, Honjo G, Misaki T, Toda Y, Izumi K, Kamoda Y, et al. A unique subtype of diffuse large B-cell lymphoma primarily involving the bone mar- row, spleen, and liver, defined by fluorodeoxyglucosepositron emission tomography combined with computed tomography. Leuk Lymphoma 2016;57(11):2593-2602.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Matsue K, Abe Y, Narita K, et al. Bone marrow infiltration pattern in patients with intravascular large B-cell lymphoma diagnosed by random skin biopsy. *eJHaem*. 2020;1:281–285. https://doi.org/10.1002/jha2.66